SCHEMBL857948

SCHEMBL857948

Cc1ncnc(Cl)c1Cc1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.49
CCR2 P41597 1/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
TAAR1 Q96RJ0 3/20 0.42
SRC P12931 1/20 0.41
PNMT P11086 2/20 0.41
ADCY10 Q96PN6 1/20 0.40
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5470044 0.89 ALDH1A1 (0.49) ENPP1LMNAALDH1A1SMN1; SMN2TAAR1
SCHEMBL857333 0.88 ENPP1 (0.45) ENPP1LMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL855862 0.85 ENPP1 (0.47) ENPP1LMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL856520 0.83 ALDH1A1 (0.51) ENPP1LMNAALDH1A1SMN1; SMN2TAAR1
SCHEMBL857450 0.82 SMN1; SMN2 (0.56) ENPP1LMNAALDH1A1SMN1; SMN2TAAR1
SCHEMBL857569 0.81 HTR2A (0.42) TAAR1MAPT
SCHEMBL856222 0.80 SMN1; SMN2 (0.56) ENPP1LMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL856022 0.80 ALDH1A1 (0.45) ENPP1LMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL5809191 0.77 ENPP1 (0.41) ENPP1CCR2LMNAALDH1A1SMN1; SMN2
SCHEMBL855865 0.77 ALDH1A1 (0.39) ENPP1LMNAALDH1A1SMN1; SMN2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ENPP1 3408/4885CCR2 4751/4885LMNA 2593/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ENPP1 3831/4885CCR2 4644/4885LMNA 2817/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ENPP1 3308/4885CCR2 4776/4885LMNA 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.